PRECISION BIOSCIENCES INC
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
DTIL$9.68-8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share amounts)
(unaudited)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $62,242 | $85,899 |
| Accounts receivable | — | 229 |
| Marketable securities | — | 413 |
| Prepaid expenses | 7,450 | 6,441 |
| Assets held for sale | 140 | 169 |
| Contract asset | — | 1,469 |
| Other current assets | 427 | 369 |
| Total current assets | 70,259 | 94,989 |
| Restricted cash | 22,564 | 22,569 |
| Property, equipment, and software—net | 2,356 | 3,089 |
| Intangible assets—net | 605 | 622 |
| Right-of-use assets—net | 6,462 | 7,090 |
| Investment in equity securities | 744 | 3,206 |
| Note receivable—net | 5,730 | 4,602 |
| Other assets | 208 | 221 |
| Total assets | $108,928 | $136,388 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,121 | $1,312 |
| Accrued compensation | 2,450 | 5,182 |
| Accrued research and development expenses | 991 | 2,016 |
| Deferred revenue | 5,989 | 2,957 |
| Lease liabilities | 1,411 | 1,320 |
| Other current liabilities | 721 | 989 |
| Current liabilities of discontinued operations | 885 | 1,204 |
| Total current liabilities | 13,568 | 14,980 |
| Loan payable | 22,354 | 22,321 |
| Deferred revenue | 20,225 | 23,300 |
| Lease liabilities | 5,680 | 6,404 |
| Warrant liability | 2,847 | 2,796 |
| Contract liabilities | 10,000 | 10,000 |
| Other noncurrent liabilities | 200 | 194 |
| Total liabilities | 74,874 | 79,995 |
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value— 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — |
| Common stock: $0.000005 par value— 200,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 11,663,996 shares issued and 11,636,981 shares outstanding as of June 30, 2025; 8,229,730 shares issued and 8,202,715 shares outstanding as of December 31, 2024 | 1 | 1 |
| Additional paid-in capital | 561,554 | 539,808 |
| Accumulated deficit | (526,549) | (482,464) |
| Treasury stock | (952) | (952) |
| Total stockholders’ equity | 34,054 | 56,393 |
| Total liabilities and stockholders’ equity | $108,928 | $136,388 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.